Skaff Michael C
CIK: 0002074003
Skaff Michael C's purchase track record
Skaff Michael C has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2026 | VVOS | $1.81M | -61.4% | -87.2% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VVOS | ▲ Buy | Open Market | 1,044,777 | $1.4M | 3/31/2026 | View on chart |
| VVOS | ▲ Buy | Open Market | 308,848 | $414K | 3/31/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
VVOS Announces $3.6M Annual Cost‑Reduction Plan
Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.
VVOS Announces $3.6M Annual Cost‑Reduction Plan. Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.